General information about U.S. regulatory expectations — not legal, medical, or manufacturing advice.

"Peptide API manufacturer" can mean very different things depending on the market a supplier serves. This guide covers what the primary FDA sources say about registration, API GMP, and impurity expectations for synthetic peptides. It does not rank or recommend specific manufacturers.

What must a peptide API manufacturer do to supply the US market?

Foreign establishments that manufacture, repack, relabel or salvage APIs imported or offered for import into the US must register with FDA under section 510(i) of the FD&C Act and 21 CFR 207.17, according to FDA's page on importing active pharmaceutical ingredients. The same page states that foreign drug manufacturers must also list all their commercially distributed drugs, including API, under section 510(j) and 21 CFR 207.41.

Timing differs by location: foreign manufacturers must register before importation, while domestic manufacturers must register no later than 5 calendar days after manufacturing starts under 21 CFR 207.21, per FDA's establishment registration presentation.

Is registration enforcement changing?

Possibly: FDA has a pending rulemaking, but its final contents and effective date are not confirmed. The agency's 21 CFR Part 207 rulemaking (Docket FDA-2025-N-6075, RIN 0910-AI94) addresses registration and listing for establishments in distributed manufacturing and certain foreign establishments. The Federal Register public-inspection document notes that many foreign establishments making APIs only for other foreign establishments have not registered or listed.

That is a signal worth watching, not a settled rule. Any change to Part 207 should be confirmed from the final Federal Register notice rather than assumed.

What GMP standard applies to peptide APIs?

FDA's ICH Q7 guidance covers APIs made by chemical synthesis, extraction, cell culture or fermentation, recovery from natural sources, or any combination of these. The document was revised to change its ICH codification from Q7A to Q7, so older references to "Q7A" point to the same guidance.

Q7 has a stated limit: FDA's Q7 Q&A says it does not apply to manufacturing steps before the defined API starting material, though FDA still expects suitable controls there.

Is ICH Q7 legally binding?

By itself, no. FDA states in the same Q7 Q&A guidance that its guidance documents are recommendations and not legally enforceable unless specific regulatory or statutory requirements are cited.

How pure does a generic synthetic peptide API need to be?

For generic synthetic peptides, FDA's draft ANDA guidance says filing is generally appropriate if a new specified peptide-related impurity in the proposed generic is no more than 0.5% of the drug substance. FDA's stated reason is that a higher level raises immunogenicity concerns that could not be addressed in an ANDA without clinical data.

The 0.5% figure comes from the draft guidance text, and an NLM-hosted excerpt discussing the 2021 guidance repeats it. Whether that figure appears in any final guidance was not confirmed, so anyone relying on it for a filing should check FDA's current guidance directly.

What does an applicant have to show for each impurity?

The applicant must justify each new specified peptide-related impurity as not affecting safety, including immunogenicity, or effectiveness. As summarized in an NCBI/PMC article quoting the 2021 guidance, the data should show the impurity lacks sequences with increased affinity for MHC, meaning T-cell epitopes.

FDA's own presentation on ANDA deficiencies describes the May 2021 peptide ANDA guidance and notes that peptide drugs are specifically excluded from the ICH Q3A/Q3B impurity qualification guidelines.

Does a "high-purity" certificate of analysis mean a peptide is FDA-grade?

No. FDA's guidance focuses on characterizing and justifying individual peptide-related impurities, not on a single purity percentage, as laid out in the draft synthetic-peptide ANDA guidance and the NCBI/PMC discussion of the 2021 guidance.

FAQ

What must a foreign peptide API manufacturer do to supply the US market? Foreign establishments that manufacture, repack, relabel or salvage APIs imported or offered for import into the US must register with FDA under section 510(i) and 21 CFR 207.17, and must list their commercially distributed drugs, including API, under section 510(j) and 21 CFR 207.41, per FDA. FDA's ICH Q7 guidance separately sets out recommended GMP for APIs made by chemical synthesis and other methods.

How pure does a generic synthetic peptide API need to be? FDA's draft guidance says filing is generally appropriate if a new specified peptide-related impurity is no more than 0.5% of the drug substance, with each new impurity justified for safety, including immunogenicity, and effectiveness. Its status in any final guidance was not confirmed.

Does a high-purity certificate of analysis mean FDA-grade? No. The guidance focuses on characterizing and justifying individual impurities rather than a single purity figure.

Is ICH Q7 legally binding? FDA says its guidances are recommendations, not legally enforceable unless specific regulatory or statutory requirements are cited.

Does Q7 cover steps before the API starting material? No, though FDA still expects suitable controls at those steps.

Browse the catalog

Browse the catalog. All catalog products are sold for research use only and are not represented as FDA-registered, FDA-approved, or compliant with any FDA guidance discussed above. For FDA registration and listing requirements, see FDA's page on importing active pharmaceutical ingredients.